Confirmed Coverage for JETREA® Based on Benefit Verification
on the link below for your geographical area/region.
JETREA (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, is a proteolytic enzyme indicated for the treatment of
symptomatic vitreomacular adhesion.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088. You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Health Care Professional.